Abstract
Viral load in respiratory syncytial virus infected premature newborns under prophylaxis with palivizumab
Highlights
Human respiratory syncytial virus (HHRSV) is the most important causative agent of lower respiratory tract infection in children and infants [1,2]. Preterm infants or those affected by some chronic conditions are especially compromised by HHRSV infection usually accounting for long periods of hospitalization and high rates of mortality [3]
The aim of this study was to evaluate HHRSV detection through the currently available tests such as Direct Immunofluorescence Assay (DFA), Polimerase Chain Reaction (PCR) and Real-Time polymerase chain reaction, among symptomatic children samples in use of Palivizumab®, and compare the viral load to another group of infected children without previous prophylaxis recruited from the community
All samples were tested by the three techniques showing a positivity of 10.1% (7/69) for DFA, 13.0% (9/69) for PCR and a positivity of 14.5% (10/69) for qPCR
Summary
Human respiratory syncytial virus (HHRSV) is the most important causative agent of lower respiratory tract infection in children and infants [1,2]. Preterm infants or those affected by some chronic conditions are especially compromised by HHRSV infection usually accounting for long periods of hospitalization and high rates of mortality [3]. The Palivizumab® is a humanized murine monoclonal antibody produced by recombinant technology that targets the A antigenic site of the F protein of HRSV. This drug demonstrates both neutralizing and fusion inhibitory activity and can prevent or reduce the severity of HRSV infection [5]. Palivizumab® has been used for some specific highrisk groups of children in Sao Paulo, Brazil, since 2007 [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
